Loading
HER2 PET is a PET scan using radiolabelled trastuzumab or smaller HER2 binders to map HER2 across all metastases at once.
HER2 PET images HER2 across every metastasis at once using a radiolabelled HER2 binder, either 89Zr-trastuzumab or smaller 68Ga- and 18F-labelled affibodies and nanobodies such as 68Ga-ABY-025 and 18F-GE-226. The result is a whole-body receptor map rather than a single biopsy, which matters because HER2 expression varies between lesions. The ZEPHIR and IMPACT trials studied these tracers, and uptake was predictive of response to T-DM1. It is most useful in heterogeneous HER2-low disease, where one biopsy may be unrepresentative and HER2-directed ADCs now have indications. Studied since 2010, it is not yet approved; trials have been small, and full-antibody tracers need days between injection and imaging, which smaller binders aim to shorten. It shows how much HER2 each tumour deposit carries without a needle.
Radiolabelled HER2 binder; whole-body receptor map.
Query for this technology: (TITLE:"HER2 PET" OR ABSTRACT:"HER2 PET" OR TITLE:"89Zr-trastuzumab" OR ABSTRACT:"89Zr-trastuzumab" OR TITLE:"HER2 imaging PET" OR ABSTRACT:"HER2 imaging PET"). Results are unfiltered search hits about HER2 PET, not a curated reading list.
Shares Shaoli Song, Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET, Immuno-PET, ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs.
Shares HER2-low and HER2-ultralow metastatic breast cancer, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
Shares HER2-low and HER2-ultralow metastatic breast cancer, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
Shares Early HER2-positive breast cancer, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
Shares Shaoli Song, Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET, FES PET (oestrogen receptor imaging), PET (positron emission tomography).
Shares HER2-low and HER2-ultralow metastatic breast cancer, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
Shares HER2-low and HER2-ultralow metastatic breast cancer, Biomarkers are not validated or standardised, HER2, HR-positive / HER2-negative breast cancer.